(NASDAQ: KZIA) Kazia Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.81%.
Kazia Therapeutics's earnings in 2026 is -$16,170,694.On average, 4 Wall Street analysts forecast KZIA's earnings for 2026 to be -$3,931,321,841, with the lowest KZIA earnings forecast at -$7,498,758,356, and the highest KZIA earnings forecast at -$59,513,955. On average, 4 Wall Street analysts forecast KZIA's earnings for 2027 to be -$3,208,652,385, with the lowest KZIA earnings forecast at -$6,165,645,759, and the highest KZIA earnings forecast at $0.
In 2028, KZIA is forecast to generate -$3,035,211,716 in earnings, with the lowest earnings forecast at -$5,832,367,610 and the highest earnings forecast at $0.